TP53 in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDSs) are heterogeneous for their morphology, clinical characteristics, survival of patients, and evolution to acute myeloid leukemia. Different prognostic scoring systems including the International Prognostic Scoring System (IPSS), the Revised IPSS, the WHO Typed Prognos...
Saved in:
Main Authors: | Yan Jiang, Su-Jun Gao, Benoit Soubise, Nathalie Douet-Guilbert, Zi-Ling Liu, Marie-Bérengère Troadec |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/ec8b25c4a03740d0ac190ec97f3a4263 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes
by: Mariko Yabe, et al.
Published: (2021) -
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
by: Edit Porpaczy, et al.
Published: (2021) -
<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
by: Ramya Thota, et al.
Published: (2021) -
<i>TP53</i> Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
by: Humaira Noor, et al.
Published: (2021) -
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
by: Palacios-Campos,Adriana, et al.
Published: (2020)